In order to effectively evaluate any new business development opportunities and ensure that the true value of a transaction has been realized, while forecasting the probability of both development and commercial success, life science companies need to ensure the right internal experts are involved in the evaluation process. This calls for the development and continuous improvement of a formal process that will allow organizations to efficiently and effectively evaluate, negotiate, manage, and close a transaction. The 2nd BD&L Summit serves as an open forum for cross-functional business development teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements and M&A deals.